Risk of adverse events with fibrates

This publication has 10 references indexed in Scilit:

• Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
  Clinical Pharmacology & Therapeutics, 2003
• Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin
  The American Journal of Cardiology, 2003
• An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
  Clinical Therapeutics, 2003
• Gemfibrozil greatly increases plasma concentrations of cerivastatin
  Clinical Pharmacology & Therapeutics, 2002
• Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
  Drug Metabolism and Disposition, 2002
• Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
  The Journal of Pharmacology and Experimental Therapeutics, 2002
• Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose)
  The American Journal of Cardiology, 2002
• Plasma concentrations of active simvastatin acid are increased by gemfibrozil
  Clinical Pharmacology & Therapeutics, 2000
• Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers
  The Journal of Clinical Pharmacology, 2000
• Pharmacokinetics of the combination of fluvastatin and gemfibrozil
  The American Journal of Cardiology, 1995